| 2024 | 2023 | ||
| Notes | £’000 | £’000 | |
Revenue | 4 | ||
Cost of sales | ( | ( | |
Gross profit | |||
| Other operating income | |||
Government grants | 5 | ||
Profit on sale of IP | 6 | ||
Gain on derivative financial instrument | 6 | ||
| Operating expenses | |||
Research and development expenses | 6 | ( | ( |
Administrative expenses | ( | ( | |
Operating profit | 6 | ||
– Before share-based payments and non-recurring items | ( | ||
– Share-based payments | 24 | ( | ( |
– Profit on sale of IP | 6 | ||
– Gain on derivative financial instrument | |||
– Litigation costs | 6 | ( | |
– EGM requisition | ( | ||
Finance income | 8 | ||
Finance expense | 8 | ( | ( |
Profit before taxation | |||
Taxation | 9 | ( | |
(Loss)/profit after taxation | ( | ||
Other comprehensive income | |||
Total comprehensive (loss)/profit for the year | ( | ||
| (Loss)/profit per share | |||
Basic (loss)/profit per share for the year | 10 | ( | |
Diluted (loss)/profit per share for the year | 10 | ( |
| Share- | (Accumulated | |||||||||
| Capital | Reverse | based | Shares | losses)/ | ||||||
| Share | Share | redemption | acquisition | payment | Merger | held | retained | |||
| capital | premium | reserve | reserve | reserve | reserve | by EBT | earnings | Total | ||
Group | Notes | £’000 | £’000 | £’000 | £’000 | £’000 | £’000 | £’000 | £’000 | £’000 |
At 1 August 2022 | ( | ( | ( | |||||||
Profit for the year | ||||||||||
Other comprehensive income | ||||||||||
Total comprehensive profit | ||||||||||
Capital reduction | 22 | ( | ||||||||
| Issue of capital to EBT | ||||||||||
on option exercise | ( | ( | ( | |||||||
Share-based payments | 24 | |||||||||
At 31 July 2023 | ( | ( | ( | |||||||
Loss for the year | ( | ( | ||||||||
Other comprehensive income | ||||||||||
Total comprehensive loss | ( | ( | ||||||||
Share buy-back | 22, 26 | ( | ( | ( | ( | |||||
| Issue of capital to EBT | ||||||||||
on option exercise | ( | ( | ||||||||
Transfer of expired options | 24 | ( | ||||||||
Share-based payments | 24 | |||||||||
At 31 July 2024 | ( | ( | ( | ( |
| 31 July 2024 | 31 July 2024 | 31 July 2023 | 31 July 2023 | ||
| Group | Company | Group | Company | ||
| Notes | £’000 | £’000 | £’000 | £’000 | |
| Assets | |||||
| Non-current assets | |||||
Tangible fixed assets | 11 | — | — | ||
Right of use assets | 12 | — | — | ||
Intangible assets | 13 | — | — | ||
Deferred tax assets | 9 | — | — | ||
Foreign withholding tax receivable | 9 | — | — | ||
Investment in subsidiaries | 14 | 46,473 | 41,700 | ||
46,473 | 41,700 | ||||
| Current assets | |||||
Inventories | 15 | — | — | ||
Trade and other receivables | 16 | 3,518 | 52,876 | ||
Foreign withholding tax receivable | 9 | — | — | ||
Income tax receivable | 9 | — | — | ||
Cash and cash equivalents | 17 | 20,164 | 105 | ||
23,682 | 52,981 | ||||
Total assets | 70,155 | 94,681 | |||
| Liabilities | |||||
| Current liabilities | |||||
Trade and other payables | 18 | ( | (778) | ( | (1,153) |
Loans | 19 | — | ( | (4,004) | |
Lease liabilities | 21 | ( | — | ( | — |
Income tax liability | 9 | — | ( | — | |
Deferred revenue | 20 | ( | — | ( | — |
( | (778) | ( | (5,157) | ||
| Non-current liabilities | |||||
Loans | 19 | — | ( | — | |
Lease liabilities | 21 | ( | — | ( | — |
Provisions | 23 | ( | — | ( | — |
Deferred revenue | 20 | ( | — | ( | — |
( | — | ( | — | ||
Total liabilities | ( | (778) | ( | (5,157) | |
Net (liabilities)/assets | ( | 69,377 | 89,524 | ||
| Capital and reserves | |||||
Share capital | 22 | 20,257 | 32,443 | ||
Capital redemption reserve | 22 | 12,186 | — | ||
Reverse acquisition reserve | 22 | ( | — | ( | — |
Share-based payment reserve | 24 | 1,572 | 5,610 | ||
Merger reserve | 25 | ( | — | ( | — |
Shares held by EBT | 26 | ( | (28) | ( | — |
Retained earnings | 26 | 35,390 | 51,471 | ||
Total equity | ( | 69,377 | 89,524 |
| 31 July 2024 | 31 July 2024 | 31 July 2023 | 31 July 2023 | ||
| Group | Company | Group | Company | ||
| Notes | £’000 | £’000 | £’000 | £’000 | |
Profit before tax | 8,807 | 46,182 | |||
| Adjustments for: | |||||
Net finance (income)/expense | 8 | ( | (275) | 5,337 | |
(Profit)/loss on exchange rate translations | ( | (350) | (10) | ||
Depreciation of tangible fixed assets | 11 | — | — | ||
Depreciation of right of use assets | 12 | — | — | ||
Amortisation of intangible assets | 13 | — | — | ||
Profit on disposal of intangible assets | 6 | — | ( | — | |
Impairment of intangible assets | 13 | — | — | ||
Reversal of previous impairment of investment | (3,816) | — | |||
Share-based payments | 24 | — | — | ||
Loss on disposal of tangible fixed assets | 11 | — | — | ||
Increase/(decrease) in inventory provision | — | ( | — | ||
Decrease in receivables provision | (2,993) | (52,323) | |||
| Changes in working capital: | |||||
Increase in inventories | ( | — | ( | — | |
Decrease/(increase) in trade and other receivables | 55,148 | (378) | |||
(Decrease)/increase in trade and other payables | ( | (380) | 316 | ||
Decrease in provisions | — | ( | — | ||
Increase in deferred revenue | — | — | |||
Cash inflow/(outflow) from operating activities | 56,141 | ( | (876) | ||
Foreign withholding tax paid | ( | — | ( | — | |
Tax paid | ( | — | — | ||
Research and development tax credit received | — | — | |||
Net cash inflow/(outflow) from operating activities | 56,141 | ( | (876) | ||
| Cash flow from investing activities | |||||
Purchases of tangible fixed assets | 11 | ( | — | ( | — |
Purchases of intangible fixed assets | 13 | ( | — | ( | — |
Proceeds from sale of tangible fixed assets | — | — | |||
Proceeds from sale of intangible fixed assets | — | — | |||
Interest received | 8 | 722 | — | ||
Net cash (outflow)/inflow from investing activities | ( | 722 | — | ||
| Cash flow from financing activities | |||||
Proceeds from placing of ordinary share capital | — | 199 | |||
Purchase of shares to satisfy options | ( | — | — | ||
Return of capital to shareholders | ( | (32,000) | — | ||
Fees on return of capital to shareholders | ( | (654) | — | ||
Repayment of loan - capital | ( | (3,150) | — | ||
Repayment of loan - interest | ( | (1,350) | — | ||
Payment of lease liabilities (capital) | ( | — | ( | — | |
Payment of lease liabilities (interest) | ( | — | ( | — | |
Interest paid | ( | — | ( | (4,725) | |
Net cash outflow from financing activities | ( | (37,154) | ( | (4,526) | |
Increase/(decrease) in cash and cash equivalents | 19,709 | (5,402) | |||
Cash and cash equivalents at the start of the year | 105 | 5,497 | |||
Effects of exchange rate changes | 350 | 10 | |||
Cash and cash equivalents at the end of the year | 17 | 20,164 | 105 |
| 31 July | 31 July | |
| 2024 | 2023 | |
| £’000 | £’000 | |
| Analysis of revenue | ||
Products sold | 408 | 867 |
Rendering of services | 1,410 | 1,685 |
Licences | 6,056 | 3,066 |
7,874 | 5,618 |
| 31 July | 31 July | |
| 2024 | 2023 | |
| £’000 | £’000 | |
| Revenue | ||
South Korea | 6,013 | 2,963 |
Netherlands | 926 | 1,423 |
Japan | 573 | 447 |
France | 268 | 385 |
USA | 46 | 59 |
Taiwan | 42 | 323 |
Canada | 3 | 9 |
Belgium | 2 | — |
UK | 1 | 1 |
Poland | — | 8 |
7,874 | 5,618 |
| 31 July | 31 July | |
| 2024 | 2023 | |
| £’000 | £’000 | |
Government grants | 142 | 230 |
| 31 July | 31 July | |
| 2024 | 2023 | |
| £’000 | £’000 | |
| Operating profit/(loss) is stated after charging/(crediting): | ||
Depreciation of tangible fixed assets (see note 11) | 117 | 76 |
Depreciation of right of use assets (see note 12) | 698 | 555 |
Loss on disposal of fixed assets | 2 | 8 |
Amortisation of intangible assets (see note 13) | 224 | 279 |
Impairment of intangible assets (see note 13) | 132 | 92 |
Profit on disposal of intangible assets | — | (68,687) |
Settled litigation costs | — | 49,337 |
Requisitioned general meeting | — | 490 |
Realised gain on derivative financial instrument | (1,814) | — |
Lease costs of low value/short life lease obligations | 16 | 7 |
Staff costs (see note 7) | 3,396 | 3,480 |
Foreign exchange (gains)/losses | (852) | 1,747 |
Research and development expense 1 | 1,630 | 1,802 |
Share-based payments | 957 | 953 |
Employer’s tax on share-based payments | 0 | (225) |
| 31 July | 31 July | |
| 2024 | 2023 | |
| £’000 | £’000 | |
Revenue (licence fee income) | 6,013 | 2,963 |
Administrative costs (litigation costs) | — | (49,337) |
Profit on disposal of intangible assets | — | 68,687 |
Gain on derivative financial instrument | 1,814 | — |
FX gain on cash held prior to conversion | 349 | — |
Unrealised foreign exchange gain/(loss) on accrued income | 504 | (1,929) |
Net operating profit | 8,680 | 20,384 |
Interest payable on loan notes | — | (4,725) |
Profit before tax | 8,680 | 15,659 |
| Impact on | |
| revenue | |
| 2024 | |
| Remaining patent life at start of licence | £’000 |
7 years | 1,555 |
8 years | 609 |
9 years | (127) |
10 years | (715) |
| 31 July | 31 July | |
| 2024 | 2023 | |
| £’000 | £’000 | |
Proceeds receivable (debtors due within one year) | — | 33,041 |
Deferred income (due within one year) | (5,944) | (6,080) |
Deferred income (due after more than one year) | (37,583) | (17,801) |
Disposal of intangible assets | — | (356) |
Withholding tax asset | 4,314 | 2,269 |
Cash | 58,811 | 4,458 |
Net assets | 19,598 | 15,531 |
| 31 July | 31 July | |
| 2024 | 2023 | |
| £’000 | £’000 | |
| Audit services: | ||
– Fees payable to Company auditors for the audit of the Parent and the consolidated accounts | 200 | 102 |
– Auditing the accounts of subsidiaries pursuant to legislation | 62 | 60 |
Total audit fees | 262 | 162 |
| Non-audit services: | ||
– Fees payable for working capital review | 100 | — |
Total auditors’ remuneration | 362 | 162 |
| 31 July | 31 July | |
| 2024 | 2023 | |
| £’000 | £’000 | |
Wages and salaries | 2,925 | 3,022 |
Social security costs | 295 | 340 |
Defined contribution pension costs | 176 | 118 |
3,396 | 3,480 | |
Share-based payments | 957 | 953 |
Social security costs/(credits) on share-based payments | 26 | (225) |
Total staff costs | 4,379 | 4,208 |
| Directors’ remuneration (including benefits in kind) included in the aggregate remuneration above comprised: | ||
Emoluments for qualifying services | 961 | 1,401 |
| 31 July | 31 July | |
| 2024 | 2023 | |
| Group | Number | Number |
Directors | 3 | 3 |
Laboratory and administrative staff | 43 | 36 |
46 | 39 |
| 31 July | 31 July | |
| 2024 | 2023 | |
| Group | £’000 | £’000 |
| Finance income | ||
Interest receivable on bank deposits | 835 | 38 |
| Finance expense | ||
Loan note interest | (517) | (643) |
Loan note success fee | — | (4,725) |
Unwinding interest on lease liabilities | (103) | (86) |
Interest on tax payable | (53) | — |
Other interest payable | (4) | (3) |
158 | (5,419) |
| 31 July | 31 July | |
| 2024 | 2023 | |
| Group | £’000 | £’000 |
| Current income tax | ||
UK corporation tax | — | 1,072 |
Research and development income tax credit receivable | (235) | (302) |
Foreign taxation | 601 | 291 |
Provision for unrecoverable foreign tax incurred | 2,501 | — |
Adjustment in respect of prior years | 28 | — |
2,895 | 1,061 | |
| Deferred tax | ||
Origination and reversal of temporary differences | 397 | (2,522) |
Adjustments in respect of prior periods | (174) | (51) |
Total income tax charge/(credit) | 3,118 | (1,512) |
| 31 July | 31 July | |
| 2024 | 2023 | |
| Group | £’000 | £’000 |
Profit before taxation | 1,865 | 9,573 |
Tax at standard rate of 25% (2023: 21%) | 466 | 2,011 |
| Effects of: | ||
Expenses not deductible for tax purposes | 16 | 1,237 |
Capital allowances in excess of depreciation | (10) | 13 |
Research and development tax credit receivable | 78 | (302) |
Share options exercised (CTA 2009 Pt 12 deduction) | — | (75) |
Losses recognised | (412) | (4,636) |
Credit for foreign tax expensed | (150) | — |
Provision for unrecoverable foreign tax incurred | 2,501 | — |
Foreign tax charges | 601 | 291 |
Adjustment in respect of prior years | 28 | (51) |
Tax charge/(credit) in income statement | 3,118 | (1,512) |
| 31 July | 31 July | |
| 2024 | 2023 | |
| £’000 | £’000 | |
Accelerated capital allowances | 311 | (37) |
Short-term temporary differences | (475) | (272) |
Tax losses | (2,186) | (2,264) |
(2,350) | (2,573) | |
Foreign withholding tax receivable – current | (149) | (592) |
Foreign withholding tax receivable – non-current | (1,664) | (1,756) |
Total foreign withholding tax receivable | (1,813) | (2,348) |
| Impact on | ||
| deferred tax | ||
| assets | ||
| 2024 | ||
| Number of years over which losses are recognised | £’000 | |
2 years | (1,331) | |
3 years | — | |
4 years | 1,350 | |
5 years | 2,715 |
| 31 July | 31 July | |
| 2024 | 2023 | |
| Group | £’000 | £’000 |
(Loss)/profit for the financial year attributable to equity shareholders | (1,253) | 11,085 |
Share-based payments | 957 | 953 |
(Loss)/profit for the financial year before share-based payments | (296) | 12,038 |
| Weighted average number of shares | ||
Ordinary shares in issue | 288,791,171 | 322,472,939 |
Options exercisable at the reporting date | 160,664 | 195,000 |
Options not yet exercisable at the reporting date | 12,717,665 | 11,720,600 |
Diluted weighted average number of shares | 301,669,500 | 334,388,539 |
Adjusted (loss)/profit per share before share-based payments (pence) | (0.10) | 3.73 |
Basic (loss)/profit per share (pence) | (0.43) | 3.44 |
Diluted adjusted (loss)/profit per share before share-based payments (pence) | (0.10) | 3.60 |
Diluted (loss)/profit per share (pence) | (0.43) | 3.32 |
| Office | ||||
| equipment, | ||||
| Laboratory | fixtures and | Plant and | ||
| infrastructure | fittings | machinery | Total | |
| Group | £’000 | £’000 | £’000 | £’000 |
| Cost | ||||
At 1 August 2022 | 3,338 | 399 | 7,228 | 10,965 |
Additions | 25 | 50 | 230 | 305 |
Disposals | (1,825) | (88) | (1,385) | (3,298) |
At 31 July 2023 | 1,538 | 361 | 6,073 | 7,972 |
Additions | 375 | 95 | 996 | 1,466 |
Disposals | — | (29) | (46) | (75) |
At 31 July 2024 | 1,913 | 427 | 7,023 | 9,363 |
| Accumulated depreciation | ||||
At 1 August 2022 | 3,338 | 388 | 7,141 | 10,867 |
Charged during the year | 4 | 8 | 64 | 76 |
Disposals | (1,825) | (86) | (1,364) | (3,275) |
At 31 July 2023 | 1,517 | 310 | 5,841 | 7,668 |
Charged during the year | 11 | 27 | 79 | 117 |
Disposals | — | (29) | (44) | (73) |
At 31 July 2024 | 1,528 | 308 | 5,876 | 7,712 |
| Net book value | ||||
At 31 July 2024 | 385 | 119 | 1,147 | 1,651 |
At 31 July 2023 | 21 | 51 | 232 | 304 |
| Office | Property | ||
| equipment | leases | Total | |
| Right of use assets | £’000 | £’000 | £’000 |
| Cost | |||
At 1 August 2023 | 34 | 3,208 | 3,242 |
Additions | — | 811 | 811 |
Disposals | — | — | — |
At 31 July 2024 | 34 | 4,019 | 4,053 |
| Accumulated depreciation | |||
At 1 August 2023 | 6 | 1,161 | 1,167 |
Charged during the year | 11 | 687 | 698 |
Disposals | — | — | — |
At 31 July 2024 | 17 | 1,848 | 1,865 |
| Net book value | |||
At 31 July 2024 | 17 | 2,171 | 2,188 |
At 1 August 2023 | 28 | 2,047 | 2,075 |
| Total | |
| Lease liabilities | £’000 |
Opening liabilities at 1 August 2023 | (1,871) |
Additions | (596) |
Lease payments | 661 |
Interest charge | (103) |
Closing liabilities at 31 July 2024 | (1,909) |
| More than | |||||||
| Within 1 year | 1 to 2 years | 2 to 3 years | 3 to 4 years | 4 to 5 years | 5 years | Total | |
| £’000 | £’000 | £’000 | £’000 | £’000 | £’000 | £’000 | |
31 July 2024 | 709 | 678 | 677 | — | — | — | 2,064 |
31 July 2023 | 509 | 509 | 500 | 496 | — | — | 2,014 |
| Within | More than | ||
| five years | five years | Total | |
| 31 July 2024 | £’000 | £’000 | £’000 |
Extension options expected not to be exercised | — | — | — |
Termination options expected not to be exercised | 1,254 | — | 1,254 |
Total | 1,254 | — | 1,254 |
| Within | More than | ||
| five years | five years | Total | |
| £’000 | £’000 | £’000 | |
Extension options expected not to be exercised | — | — | — |
Termination options expected not to be exercised | 1,739 | — | 1,739 |
Total | 1,739 | — | 1,739 |
| Patents | |
| Group | £’000 |
| Cost | |
At 1 August 2022 | 4,779 |
Additions | 76 |
Disposals | (1,034) |
At 31 July 2023 | 3,821 |
Additions | 135 |
Disposals | (238) |
At 31 July 2024 | 3,718 |
| Accumulated amortisation | |
At 1 August 2022 | 3,163 |
Charged during the year | 279 |
Impairment charge | 92 |
Disposals | (679) |
At 31 July 2023 | 2,855 |
Charged during the year | 224 |
Impairment charge | 132 |
Disposals | (238) |
At 31 July 2024 | 2,973 |
| Net book value | |
At 31 July 2024 | 745 |
At 31 July 2023 | 966 |
| Share | Loan | ||||
| Shares | impairment | Loans | impairment | Total | |
| Company | £’000 | £’000 | £’000 | £’000 | £’000 |
At 1 August 2022 | 63,235 | (24,006) | 25,693 | (24,175) | 40,747 |
Increase in respect of share-based payments | — | — | 953 | — | 953 |
At 31 July 2023 | 63,235 | (24,006) | 26,646 | (24,175) | 41,700 |
Increase in respect of share-based payments | — | — | 957 | — | 957 |
Reversal of previous impairments | — | 3,816 | — | — | 3,816 |
At 31 July 2024 | 63,235 | (20,190) | 27,603 | (24,175) | 46,473 |
| Share | Loan | ||||
| Shares | impairment | Loans | impairment | Total | |
| By subsidiary | £’000 | £’000 | £’000 | £’000 | £’000 |
Nanoco Tech Limited | 63,235 | (20,190) | — | — | 43,045 |
Nanoco Life Sciences Limited | — | — | 20,286 | (20,286) | — |
Nanoco Technologies Limited | — | — | 7,317 | (3,889) | 3,428 |
At 31 July 2024 | 63,235 | (20,190) | 27,603 | (24,175) | 46,473 |
| Share of issued | ||||
| ordinary share capital | ||||
| 31 July | 31 July | |||
Subsidiary undertakings | Country of incorporation | Principal activity | 2024 | 2023 |
Nanoco Life Sciences Limited | England and Wales | Research and development | 100% | 100% |
Nanoco Tech Limited | England and Wales | Holding company | 100% | 100% |
Nanoco Technologies Limited 1 | England and Wales | Manufacture and development of nanoparticles | 100% | 100% |
Nanoco 2D Materials Limited | England and Wales | Research and development | 100% | 100% |
Nanoco US Inc. 2 | USA | Management services | 100% | 100% |
| 31 July 2024 | 31 July 2024 | 31 July 2023 | 31 July 2023 | |
| Group | Company | Group | Company | |
| £’000 | £’000 | £’000 | £’000 | |
Finished goods | — | — | 37 | — |
Raw materials and consumables | 305 | — | 271 | — |
Total | 305 | — | 308 | — |
| 31 July 2024 | 31 July 2024 | 31 July 2023 | 31 July 2023 | |
| Group | Company | Group | Company | |
| £’000 | £’000 | £’000 | £’000 | |
Trade receivables | 301 | — | 87 | — |
Accrued income | 40 | — | 33,139 | — |
Accrued interest | 50 | 50 | — | — |
Prepayments | 372 | — | 430 | — |
Loan to EBT | — | 3,322 | — | — |
Inter-company loan to subsidiary | — | 11,497 | — | 67, 220 |
Less impairment provision | — | (11,497) | — | (14,490) |
Other receivables | 320 | 146 | 330 | 146 |
1,083 | 3,518 | 33,986 | 52,876 |
| 31 July 2024 | 31 July 2024 | 31 July 2023 | 31 July 2023 | |
| Group | Company | Group | Company | |
| £’000 | £’000 | £’000 | £’000 | |
US Dollars | 300 | — | 87 | — |
Sterling | 1 | — | — | — |
301 | — | 87 | — |
| Not | Past due | |||
| yet due | Due | > 120 | Total | |
| £’000 | £’000 | £’000 | £’000 | |
2024 | 1 | 296 | 4 | 301 |
2023 | 58 | 29 | — | 87 |
| 31 July 2024 | 31 July 2024 | 31 July 2023 | 31 July 2023 | |
| Group | Company | Group | Company | |
| £’000 | £’000 | £’000 | £’000 | |
Cash and cash equivalents | 20,293 | 20,164 | 8,207 | 105 |
| 31 July 2024 | 31 July 2024 | 31 July 2023 | 31 July 2023 | |
| Group | Company | Group | Company | |
| £’000 | £’000 | £’000 | £’000 | |
| Current | ||||
Trade payables | 752 | — | 864 | — |
Other payables | 182 | 146 | 338 | 146 |
Accruals | 644 | 4 | 1,581 | 381 |
Inter-company payable | — | 628 | — | 626 |
1,578 | 778 | 2,783 | 1,153 |
| 31 July 2024 | 31 July 2024 | 31 July 2023 | 31 July 2023 | |
| Group | Company | Group | Company | |
| £’000 | £’000 | £’000 | £’000 | |
Convertible Series A loan note 2028 | — | — | 400 | — |
Accrued interest on Convertible Series A loan note 2028 | — | — | 157 | — |
Loan notes (net of costs) | — | — | 2,989 | 2,989 |
Accrued interest on loan notes | — | — | 1,015 | 1,015 |
— | — | 4,561 | 4,004 |
| Group | Company | |
| £’000 | £’000 | |
| Movement in loans | ||
At 1 August 2022 | 3,919 | 3,392 |
Accrued interest on loan note | 612 | 612 |
Success fee due following Samsung agreement | 4,725 | 4,725 |
Success fee paid | (4,725) | (4,725) |
Interest on convertible loan | 30 | — |
At 31 July 2023 | 4,561 | 4,004 |
Accrued interest on loan note | 496 | 496 |
Loan note paid | (4,500) | (4,500) |
Interest on convertible loan | 21 | — |
Convertible loan paid | (578) | — |
At 31 July 2024 | — | — |
| 31 July 2024 | 31 July 2024 | 31 July 2023 | 31 July 2023 | |
| Group | Company | Group | Company | |
| £’000 | £’000 | £’000 | £’000 | |
| Current | ||||
Upfront licence fees | 5,934 | — | 6,123 | — |
| Non-current | ||||
Upfront licence fees | 37,594 | — | 17,801 | — |
43,528 | — | 23,924 | — |
| 31 July 2024 | 31 July 2023 | |
| £’000 | £’000 | |
Opening deferred revenue | 23,924 | 604 |
Revenue deferred | 25,660 | 26,843 |
Revenue booked current year | (6,056) | (3,523) |
Closing deferred revenue | 43,528 | 23,924 |
| 31 July 2024 | 31 July 2024 | 31 July 2023 | 31 July 2023 | |
| Group | Company | Group | Company | |
| £’000 | £’000 | £’000 | £’000 | |
| Current | ||||
Property leases | 612 | — | 448 | — |
Equipment leases | 9 | — | 8 | — |
Total current | 621 | — | 456 | — |
| Non-current | ||||
Property leases | 1,284 | — | 1,399 | — |
Equipment leases | 4 | — | 16 | — |
Total non-current | 1,288 | — | 1,415 | — |
| Capital | Reverse | |||||
| Share | Share | redemption | acquisition | |||
| capital | premium | reserve | reserve | Total | ||
Group | Number | £’000 | £’000 | £’000 | £’000 | £’000 |
| Allotted, called up and fully paid ordinary shares of 10p | ||||||
At 1 August 2022 | 322,445,744 | 32,244 | 121,145 | — | (77,868) | 75,521 |
Capital reduction | — | — | (121,145) | — | — | (121,145) |
Shares issued on exercise of options | 1,985,206 | 199 | — | — | — | 199 |
| At 31 July 2023 | 324,430,950 | 32,443 | — | — | (77,868) | (45,425) |
Tender offer shares cancelled | (111,250,000) | (11,125) | — | 11,125 | — | — |
Buy-back shares cancelled | (10,609,453) | (1,061) | — | 1,061 | — | — |
At 31 July 2024 | 202,571,497 | 20,257 | — | 12,186 | (77,868) | (45,425) |
| Property | ||
| dilapidations | Total | |
| £’000 | £’000 | |
At 1 August 2023 | 445 | 445 |
Provided during the period | 214 | 214 |
At 31 July 2024 | 659 | 659 |
Group and Company | £’000 |
At 1 August 2022 | 4,916 |
Share-based payments | 953 |
Exercise of share options | (259) |
At 31 July 2023 | 5,610 |
Share-based payments | 957 |
Exercise of share options | (207) |
Transfer of expired options | (4,788) |
At 31 July 2024 | 1,572 |
| 2024 total | 2023 total | |
| Group and Company | Number | Number |
Outstanding at 1 August | 11,915,600 | 19,820,352 |
Granted during the year | 9,056,742 | 5,314,890 |
Exercised during the year | (928,580) | (1,985,206) |
Forfeited during the year | (1,797,099) | (237,388) |
Expired during the year | (35,000) | (2,853,193) |
Lapsed during the year | (5,333,334) | (8,143,855) |
Outstanding at 31 July 2024 | 12,878,329 | 11,915,600 |
Exercisable at 31 July 2024 | 160,664 | 195,000 |
| 2024 | 2023 | |
| Group and Company | Pence | Pence |
Outstanding at 1 August | 1.0 | 8.9 |
Granted during the year | — | — |
Exercised during the year | — | — |
Expired during the year | 89.0 | 57.0 |
Lapsed during the year | 0.1 | 0.2 |
Outstanding at 31 July 2024 | 0.7 | 1.0 |
| Market | Non-market | |||
| performance-linked grants | performance-linked grants | |||
Group and Company | 2024 | 2023 | 2024 | 2023 |
Expected volatility | 57.55% | 89.5% | N/A | N/A |
Risk-free interest rate | 4.18% | 3.19% | N/A | N/A |
Expected life of options (years average) | 3 | 3 | 2 | 2 |
Weighted average exercise price | £nil | £nil | £nil | £nil |
Weighted average share price at date of grant | 20.5p | 35.6p | 20.5p | 35.6p |
Expected dividends | £nil | £nil | £nil | £nil |
Model used | Stochastic | Stochastic | Black-Scholes | Black-Scholes |
| Impact on | |
| share-based | |
| payment expense | |
| 2024 | |
| Increase/(decrease) at vesting % | £’000 |
100% | 142 |
60% | 2 |
25% | (121) |
0% | (209) |
Group | £’000 |
At 1 August 2022, 31 July 2023 and 31 July 2024 | (1,242) |
Company | £’000 |
At 1 August 2022 | 4,402 |
Capital reduction | (4,402) |
At 31 July 2023 | — |
Cancellation of shares following tender offer and buy-back | 12,186 |
At 31 July 2024 | 12,186 |
| Foreign | Total | ||||
| Profit | currency | (accumulated | |||
| and | translation | Treasury | Shares held | losses)/retained | |
| loss | reserve | shares | by EBT | earnings | |
| Group | £’000 | £’000 | £’000 | £’000 | £’000 |
At 1 August 2022 | (74,699) | 4 | (20) | — | (74,715) |
Profit for the year | 11,085 | — | — | — | 11,085 |
Capital reduction | 121,145 | — | — | — | 121,145 |
Issue of shares to EBT | — | — | — | (199) | (199) |
Shares utilised by EBT to satisfy options | 60 | — | — | 94 | 154 |
At 31 July 2023 | 57,591 | 4 | (20) | (105) | 57,470 |
Profit for the year | (1,253) | — | — | — | (1,253) |
Shares utilised by EBT to satisfy options | — | — | — | 105 | 105 |
Transfer of expired options | 4,788 | — | — | — | 4,788 |
Tender offer and share buy-back | (29,703) | — | (8) | (3,320) | (33,031) |
Share option exercise | 5 | — | — | — | 5 |
At 31 July 2024 | 31,428 | 4 | (28) | (3,320) | 28,084 |
| Total | |||
| (accumulated | |||
| Accumulated | Treasury | losses)/retained | |
| losses | shares | earnings | |
| Company | £’000 | £’000 | £’000 |
At 1 August 2022 | (120,298) | (20) | (120,318) |
Profit for the year | 46,182 | — | 46,182 |
Capital reduction | 125,547 | — | 125,547 |
Exercise of share options | 60 | — | 60 |
At 31 July 2023 | 51,491 | (20) | 51,471 |
Profit for the year | 8,807 | — | 8,807 |
Transfer of expired options | 4,788 | — | 4,788 |
Tender offer and share buy-back | (29,703) | (8) | (29,711) |
Exercise of share options | 7 | — | 7 |
At 31 July 2024 | 35,390 | (28) | 35,362 |
| Group | Group | Financial assets | ||
| financial | financial | and liabilities at | ||
| assets at | liabilities at | amortised cost | ||
| amortised | amortised | |||
| cost | cost | Group | Company | |
| Financial assets/(liabilities) | £’000 | £’000 | £’000 | £’000 |
| 31 July 2024 | ||||
Cash and cash equivalents | 20,293 | — | 20,293 | 20,164 |
Trade receivables | 301 | — | 301 | — |
Other receivables | 174 | — | 174 | — |
Inter-company short-term loan to subsidiary | — | — | — | 11,497 |
Less impairment provision | — | — | — | (11,497) |
Trade and other payables | — | (1,432) | (1,432) | (4) |
Lease liabilities | — | (1,909) | (1,909) | — |
Inter-company payable | — | — | — | (628) |
20,768 | (3,341) | 17,427 | 19,532 |
| Group | Group | Financial assets | ||
| financial | financial | and liabilities at | ||
| assets at | liabilities at | amortised cost | ||
| amortised | amortised | |||
| cost | cost | Group | Company | |
| Financial assets/(liabilities) | £’000 | £’000 | £’000 | £’000 |
| 31 July 2023 | ||||
Cash and cash equivalents | 8,207 | — | 8,207 | 105 |
Trade receivables | 87 | — | 87 | — |
Other receivables | 184 | — | 184 | — |
Inter-company short-term loan to subsidiary | — | — | — | 67,220 |
Less impairment provision | — | — | — | (14,490) |
Trade and other payables | — | (2,637) | (2,637) | (378) |
Lease liabilities | — | (1,871) | (1,871) | — |
Loan notes and accrued interest | — | (4,561) | (4,561) | (4,004) |
Inter-company payable | — | — | — | (626) |
8,478 | (9,069) | (591) | 47,827 |
31 July 2024 | 31 July 2023 | |||||||
| GBP | EUR | USD | Total | GBP | EUR | USD | Total | |
| Group | £’000 | £’000 | £’000 | £’000 | £’000 | £’000 | £’000 | £’000 |
Cash and cash equivalents | 20,255 | — | 38 | 20,293 | 7,948 | 1 | 258 | 8,207 |
Trade receivables | 1 | — | 300 | 301 | — | — | 87 | 87 |
Accrued income | — | — | 40 | 40 | 97 | — | 33,042 | 33,139 |
Trade payables | (712) | (11) | (29) | (752) | (775) | (5) | (84) | (864) |
19,544 | (11) | 349 | 19,882 | 7,270 | (4) | 33,303 | 40,569 |
| Impact on | Impact on | |
| loss before | loss before | |
| tax and | tax and | |
| group equity | group equity | |
| 2024 | 2023 | |
| Increase/(decrease) | £’000 | £’000 |
10% | 38 | 3,700 |
5% | 18 | 1,753 |
(5%) | (16) | (1,586) |
(10%) | (31) | (3,027) |
31 July 2024 | 31 July 2023 | |||||
| Fixed | Floating | Fixed | Floating | |||
| rate | rate | Total | rate | rate | Total | |
| Group | £’000 | £’000 | £’000 | £’000 | £’000 | £’000 |
Cash and cash equivalents | — | 20,293 | 20,293 | — | 8,207 | 8,207 |
Loan notes | — | — | — | 4,561 | — | 4,561 |
| Company | ||||||
Cash and cash equivalents | — | 20,164 | 20,164 | — | 105 | 105 |
Loan notes | — | — | — | 4,004 | — | 4,004 |
| Impact on | Impact on | |
| profit before | profit before | |
| tax and | tax and | |
| group equity | group equity | |
| 2024 | 2023 | |
| Increase/(decrease) | £’000 | £’000 |
1% | 203 | 82 |
0.5% | 101 | 41 |
(0.5%) | (101) | (41) |
(1%) | (203) | (82) |
| One to | Greater | |||
| Up to | five | than five | ||
| one year | years | years | Total | |
| 2024 | £’000 | £’000 | £’000 | £’000 |
| Financial liabilities | ||||
Trade and other payables | 1,432 | — | — | 1,432 |
Lease liabilities | 709 | 1,354 | — | 2,063 |
2,141 | 1,354 | — | 3,495 |
| One to | Greater | |||
| Up to | five | than five | ||
| one year | years | years | Total | |
| 2023 | £’000 | £’000 | £’000 | £’000 |
| Financial liabilities | ||||
Trade and other payables | 2,521 | 445 | — | 2,966 |
Lease liabilities | 509 | 1,505 | — | 2,014 |
Loans (including contractual interest) | 4,500 | 751 | — | 5,251 |
7,530 | 2,701 | — | 10,231 |
| 31 July | 31 July | ||
| 2024 | 2023 | ||
| Notes | £’000 | £’000 | |
| Loan from Nanoco Group plc to: | |||
Nanoco Technologies Limited 2 | 16 | 11,497 | 67,220 |
Less impairment provision | 16 | (11,497) | (14,490) |
— | 52,730 | ||
| Inter-company payable by Nanoco Group plc to: | |||
Nanoco Tech Limited | 18 | (450) | (450) |
Nanoco US Inc. | 18 | (178) | (176) |
| 31 July | 31 July | |
| 2024 | 2023 | |
| Company | £’000 | £’000 |
Short-term employee benefits | 765 | 753 |
Pension costs | 62 | 56 |
Cash bonus | — | 549 |
Share-based payments | 197 | 283 |
1,024 | 1,641 |
| Liabilities from financing activities | |||||
| Total | |||||
| liabilities from | Cash | ||||
| Lease | financing | and cash | Total | ||
| Loans | liabilities | activities | equivalents | net debt | |
| Group | £’000 | £’000 | £’000 | £’000 | £’000 |
At 1 August 2022 | (3,919) | (169) | (4,088) | 6,762 | 2,674 |
Financing cash flows | 4,725 | 549 | 5,274 | 1,263 | 6,537 |
New leases | — | (2,165) | (2,165) | — | (2,165) |
Foreign exchange adjustments | — | — | — | 182 | 182 |
Interest expense | (5,367) | (86) | (5,453) | — | (5,453) |
At 31 July 2023 | (4,561) | (1,871) | (6,432) | 8,207 | 1,775 |
Financing cash flows | 5,078 | 661 | 5,739 | 11,743 | 17,482 |
New leases | — | (596) | (596) | — | (596) |
Foreign exchange adjustments | — | — | — | 343 | 343 |
Interest expense | (517) | (103) | (620) | — | (620) |
At 31 July 2024 | — | (1,909) | (1,909) | 20,293 | 18,384 |
| Cash | |||
| and cash | Total | ||
| Loans | equivalents | net debt | |
| Company | £’000 | £’000 | £’000 |
Net debt as at 1 August 2022 | (3,392) | 5,497 | 2,105 |
Financing cash flows | 4,725 | (5,402) | (677) |
Foreign exchange adjustments | — | 10 | 10 |
Interest expense | (5,337) | — | (5,337) |
Net debt at 31 July 2023 | (4,004) | 105 | (3,899) |
Financing cash flows | 4,500 | 19,709 | 24,209 |
Foreign exchange adjustments | — | 350 | 350 |
Interest expense | (496) | — | (496) |
Net debt at 31 July 2024 | — | 20,164 | 20,164 |